Firas E. Zahr

Oct 31, 2024 | radcliffecardiology.com | David Erlinge |Stephan Baldus |Firas E. Zahr |Thomas Gilpin

TCT Conference 24 - Two-year outcomes of CLASP IID shows that the Edwards PASCAL system was noninferior to the Abbott Mitraclip system in transcatheter mitral valve repair for mitral regurgitation. Dr Firas Zahr (Oregon Health and Science University, US) joins us onsite at TCT Conference to discuss the outcomes from the CLASP IID 2 Year RCT and Registry (NCT02371512; Edwards Lifesciences).

Apr 6, 2024 | uscjournal.com | Harriette Van Spall |Javed Butler |Joost Daemen |Firas E. Zahr

ACC.24 — Join Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA), and Principal Investigator, Dr Javed Butler (University of Mississippi Medical Center, US), as they discuss the key findings from the EMPACT-MI trial (Boehringer Ingelheim)(NCT04509674).

Mar 6, 2024 | cfrjournal.com | Firas E. Zahr |Ankur Kalra |Haider Warraich

"Hello, everybody. My name is Firas Zahr, and I'm an interventional cardiologist at Oregon Health and Science University. Today I was presenting the one-year outcome from the ALT FLOW early feasibility study of the left atrial to coronary sinus aperture transcatheter shunt system. What is the background of this study? You know, heart failure. Left-sided heart failure is a progressive disease that has high morbidity and mortality. It's very often associated with poor quality of life.